{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:08:26Z","timestamp":1779088106101,"version":"3.51.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2020,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tumour immunotherapies have been a breakthrough in clinical oncology but only a few patients benefit from this progress. Additional interventions that sensitize immunologically cold tumours for the administration of checkpoint modifiers are urgently needed. In this issue of\n                    <jats:italic>EMBO Molecular Medicine<\/jats:italic>\n                    , Aznar\n                    <jats:italic>et\u00a0al<\/jats:italic>\n                    present the already approved yellow fever vaccine 17D as an oncolytic agent for tumour immunoactivation. In tumour\u2010bearing mice, they demonstrated a convincing synergy of the vaccine with CD137 agonistic antibodies resulting in significantly improved survival.\n                  <\/jats:p>","DOI":"10.15252\/emmm.201911496","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T03:29:41Z","timestamp":1574220581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Live vaccines\u2014a short\u2010cut to cancer viro\u2010immunotherapy"],"prefix":"10.1038","volume":"12","author":[{"given":"Thomas C","family":"Wirth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6942-1573","authenticated-orcid":false,"given":"Florian","family":"K\u00fchnel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,20]]},"reference":[{"key":"BFEMMM201911496_CR1","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS et\u00a0al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33: 2780\u20132788","journal-title":"J Clin Oncol"},{"key":"BFEMMM201911496_CR2","volume":"12","author":"MA Aznar","year":"2019","unstructured":"Aznar MA, Molina C, Teijera A, Rodriguez I, Azpilikueta A, Garasa S, Sanchez\u2010Paulete AR, Cordeiro L, Etxeberria I, Alvarez M et\u00a0al (2019) Repurposing the yellow fever vaccine for intratumoral immunotherapy. EMBO Mol Med 12: e10375","journal-title":"EMBO Mol Med"},{"key":"BFEMMM201911496_CR3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer\u2010immune set point. Nature 541: 321\u2013330","journal-title":"Nature"},{"key":"BFEMMM201911496_CR4","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/mt.2014.160","volume":"22","author":"CE Engeland","year":"2014","unstructured":"Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umansky V, Nettelbeck DM, Weichert W et\u00a0al (2014) CTLA\u20104 and PD\u2010L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther 22: 1949\u20131959","journal-title":"Mol Ther"},{"key":"BFEMMM201911496_CR5","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.15252\/emmm.201707567","volume":"9","author":"JD Freedman","year":"2017","unstructured":"Freedman JD, Hagel J, Scott EM, Psallidas I, Gupta A, Spiers L, Miller P, Kanellakis N, Ashfield R, Fisher KD et\u00a0al (2017) Oncolytic adenovirus expressing bispecific antibody targets T\u2010cell cytotoxicity in cancer biopsies. EMBO Mol Med 9: 1067\u20131087","journal-title":"EMBO Mol Med"},{"key":"BFEMMM201911496_CR6","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/0008-5472.CAN-11-2788","volume":"72","author":"LB John","year":"2012","unstructured":"John LB, Howland LJ, Flynn JK, West AC, Devaud C, Duong CP, Stewart TJ, Westwood JA, Guo ZS, Bartlett DL et\u00a0al (2012) Oncolytic virus and anti\u20104\u20101BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res 72: 1651\u20131660","journal-title":"Cancer Res"},{"key":"BFEMMM201911496_CR7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E et\u00a0al (2017) Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti\u2010PD\u20101 immunotherapy. Cell 170: 1109\u20131119","journal-title":"Cell"},{"key":"BFEMMM201911496_CR8","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","volume":"26","author":"JM Ricca","year":"2018","unstructured":"Ricca JM, Oseledchyk A, Walther T, Liu C, Mangarin L, Merghoub T, Wolchok JD, Zamarin D (2018) Pre\u2010existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy. Mol Ther 26: 1008\u20131019","journal-title":"Mol Ther"},{"key":"BFEMMM201911496_CR9","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/mt.2015.115","volume":"23","author":"N Woller","year":"2015","unstructured":"Woller N, Gurlevik E, Fleischmann\u2010Mundt B, Schumacher A, Knocke S, Kloos AM, Saborowski M, Geffers R, Manns MP, Wirth TC et\u00a0al (2015) Viral infection of tumors overcomes resistance to PD\u20101\u2010immunotherapy by broadening neoantigenome\u2010directed T\u2010cell responses. Mol Ther 23: 1630\u20131640","journal-title":"Mol Ther"},{"key":"BFEMMM201911496_CR10","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","volume":"6","author":"D Zamarin","year":"2014","unstructured":"Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP (2014) Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6: 226ra32","journal-title":"Sci Transl Med"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.201911496.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.15252\/emmm.201911496","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.15252\/emmm.201911496\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.embopress.org\/doi\/pdf\/10.15252\/emmm.201911496","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.201911496.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:25:47Z","timestamp":1779085547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.15252\/emmm.201911496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,20]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,9]]}},"alternative-id":["BFEMMM201911496"],"URL":"https:\/\/doi.org\/10.15252\/emmm.201911496","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,20]]},"assertion":[{"value":"20 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"EMMM201911496"}}